Immunosenescence: Implications for cancer immunotherapy in elderly patients;Inmunosenescencia: Implicaciones para la inmunoterapia de cáncer en los adultos mayores

Biotecnologia Aplicada

Volumn 23, Issue 3, 2006, Pages 186-201

  García, Beatriz ^a   Lage, Agustín ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

Aging; Cancer; Immunosenescence; Immunotherapy

Indexed keywords

BEC 2; CANCER VACCINE; CANVAXIN; DNA VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; MELACINE; ONCOPHAGE; PNEUMOCOCCUS VACCINE; PROVENGE; TETANUS TOXOID; THERATOPE; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; AGING; ANTIGENICITY; B LYMPHOCYTE; BREAST CANCER; CANCER; CANCER EPIDEMIOLOGY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DRUG MECHANISM; EFFECTOR CELL; ELDERLY CARE; HEPATITIS A; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; INFLUENZA; INNATE IMMUNITY; KIDNEY CANCER; LUNG SMALL CELL CANCER; LYMPHOPOIESIS; MELANOMA; NONHUMAN; PHENOTYPE; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SENESCENCE; STREPTOCOCCUS INFECTION; T LYMPHOCYTE; TETANUS; THYMUS;

EID: 33847253464     PISSN: 08644551     EISSN: 10272852     Source Type: Journal    
DOI: None     Document Type: Review

References (131)

1. Solana R, Pawelec G. Molecular and cellular basis of immunoenescence. Mech. Ageing Dev 1998;102:115-29.
2. Linton PJ, Dorshkind K. Age-related changes in lymphocyte development and function. Nat Immunol 2004;5(2):133-9.
3. Geiger H, Van Zant G. The aging of lympho-hematopoietic stem cells. Nat Immunol 2002;3:329-33.
4. Tyan ML. Age-related decrease in mouse T cell progenitors. J Immunol 1977;118:846-51.
5. Yu S, Abel L, Globerson A. Thymocyte progenitors and T cell development in aging. Mech Ageing Dev 1997;94:103-111.
6. Andrew D, Aspinall R. Age-associated thymic atrophy is linked to a decline in IL-7 production. Exp Gerontol 2001;37:455-63.
7. Ortman CL, Dittmar KA, Witte PL, Le PT. Molecular caracterization of the mouse involuted thymus: aberrations in expression of transcription regulators in thymocyte and epithelial compartments. Int Immunol 2002;14:813-22.
8. Klug DB, Carter C, Gimenez-Conti IB, Richie ER. Thymocyte-independent and thymocyte dependent phases of epithelial patterning in fetal thymus. J Immunol 2002;169:2842-5.
9. Shores EW, Van Ewijk W, Singer A. maturation of medullary thymic epithelium requires thymocytes expressing fully assembled CD3-TCR complexes. Int Immunol 1994;6:1393-402.
10. Min H, Montecino E, Dorshkind K. Effects of aging on early B and T-cell development, Immunol Rev 2005;205:7-17.
11. Mocchegiani E, Santarelli L, Muzzioli M, Fabriss N. Reversibility of the Thymic involution and of aged-related peripheral immune dysfuntions by Zinc supplementation in old mice. Int J Immunopharmacol 1995;17:703-18.
12. Kasai M, Shirasawa T, Kitamura M, Ishido K, Kominami E, Hirokawa K. Proenzyme from cathepsin L produce by thymic epithelial cells promotes proliferation of im mature Thymocytes in the presence of IL-1, IL-7 and anti- CD3 antibody. Cell Immunol 1993;150:124-36.
13. Goya RG, Gagnerault MC, Sosa YE, Bevilacqua JA, Dardenne M. Effects of growth hormone and thyroxine on thymulin secretion in aging rats. Neuroendocrinology 1993;58:338-43.
14. Montecino-Rodríguez E, Clark R, Dorshkind K. Effects of insulin-like Growth factor administration and bone marrow transplantation in thymopoiesis in aged mice. Endocrinology 1998;139:4120-6.
15. Savino W, Dardenne M. Neuroendocrine control of thymus physiology. Endocrine Rev 2000;21:412-43.
16. Kelley KW et al. GH3 pituitary adenoma cell can reverse thymic aging in rats. Proc Natl Acad Sci USA 1986;85:5663-7.
17. Aspinall R, Andrew D. Thymic atrophy in the mouse is a sluble problem of the thymic environment. Vaccine 2000;18:1629-37.
18. Andrew D, Aspinall R. IL-7 and not stem cell factor reverses both the increase in apoptosis and the decline in thymopoiesis seen in aged mice. J Immunol 2001;166:1524-30.
19. Motta M, Ferlito L, Malaguarnera L, Vinci E, Bosco S, Maugeri D, Malaguarnera M. Alterations of the lymphocytic set-up in elderly patients with cancer. Arch. Gerontol. Geriatr 2003;36:7-14.
20. Effros RB, Cai Z, Linton PJ. CD8 T cells and aging. Crit Rev Immunol 2003;23:45-64.
21. Grubeck-Lobeinstein B, Wick G. The aging of the immune system. Adv Immunol 2002;80:243-84.
22. hiT lymphocytes accumulate with age in mice and respond poorly to Concanavalin A. Eur J Immunol 1998;19:977-82.
23. Miller RA, García G, Kirk CJ, Witkowski JM. Early activation defects in T Lym phocytes from aged mice. Immunol Rev 1997;160:79-90.
24. Hirokawa K. Age-related changes of signal transduction in T cells. Exp Gerontol 1999;34:7-18.
25. Boren E, Gershwin ME. Inflamm-aging: autoimmunity, and the immune-risk phenotype. Autoimmunity Rev 2004;3:401-6.
26. Chakravarti B, Abraham GN. Aging and T cell mediated immunity. Mech. Ageing Dev 1999;108:183-206.
27. Nagel JE, Chopra RK, Chrest FJ, McCoy MT, Schneider EL, Holbrook NJ, et al. Decreased proliferation, interleukin 2 synthesis, and interleukin 2 receptor expression are accompanied by decreased mRNA expression in phytohemagglutinin-stimulated cells from elderly donors. J Clin Invest 1998;81:1096-102.
28. Fagnoni FF, Vescovini R, Passeri G, Bologna G, Pedrazzoni M, Lavagetto G, Casti A, Franscechi C, Passeri M, Sansoni P. Sortage of circulating naive CD8(+) T cells provides new insights on immunodeficiency in aging. Blood 2000;95:2860-8.
29. Franceschi C, Bonafe M, Valensin S, Olivieri F, De Luca M, Ottaviani E, et al. Inflammaging. An evolutionary perspective on immunosenescence. Ann NY Acad Sci 2000;908:244-54.
30. Wagner WM, Ouyang Q, Sekeri-Pataryas K, Sourlingas TG, Pawelec G. Basic biology and clinical impact of immunosenescence. Biogerontology 2004;5:63-6.
31. Hakim FT, Flomerfelt FA, Boyiadzis M, Gress RE. Aging, immunity and cancer. Curr Opin Immunol 2004;16:151-6.
32. Callahan JE, Kappler JW, Marrack P. Unexpected expansions of CD8-bearing cells in old mice. J Immunol 1993;151:6657-69.
33. Shwab R, et al. Expanded CD4+ and CD8+ T cell clones in elderly humans. J Immunol 1997;158(9):4493-9.
34. Ouyang Q, Wagner WM, Wikby A, Walter S, Aubert, Dodi AI, Travers P, Pawelec G. Large number of dysfunctional CD8 + T lymphocytes bearing receptors for a single dominant CMV epitope in the very old. J Clin Immunol 2003;23:247-57.
35. Ouyang Q, Wagner WM, Walter S, Muller CA, Wikby A, Aubert G, Klatt T, Stevanovic S, Dodi T, Pawelec G. An age-related increase in the number of CD8 T cells carrying receptors for an immunodomnant Epstein Barr Virus (EBV) epitope is counteracted by a decreased frequency of their antigen-specific responsiveness. Mech. Ageing Dev 2003;124:477-85.
36. Effros RB. Long-term immunological memory against viruses. Mech Ageing Dev 2000;121(1-3):161-71.
37. Huppert FA, Pinto EM, Morgan K, Bryan C. Survival in population sample is predicted by proportion of lymphocytes subsets. Mech. Ageing Dev 2003;124:449-51.
38. Wikby A, Johansson B, Olsson J, Lofgren S, Nilsson BO, Ferguson F. Expansions of peripheral blood CD8 T lymphocyte subpopulations and an association with cytomegalovirus seropositivity in the elderly: the Swedish NONA immune study. Exp Gerontol 2002;37:445-53.
39. Effros RB, Boucher N, Porter V, Zhu X, Spaulding C, Walford RL, Kronenberg M, Cohen D, Schachter F. Decline in CD28+ T cells in centenarians and in long-term T cell cultures: a possible cause for both in vivo and in vitro immunosenescence. Exp Gerontol 1994;29:601-9.
40. Effros RB, Pawelec G. Replicative senescence of Tcells: does the Hayflick Limit lead to immune exhaustion? Immunol Today 1997;18:450-4.
41. Fagnoni FF, Vescovini R, Mazzola M, Bologna G, Nigro E, Lavagetto G, Franceschi C, Passeri M, Sansoni P. Expansion of cytotoxic CD8+CD28" T cells in healthy ageing people, including Centenarians. Immunology 1996;88:501-7.
42. Akbar AN, Soares MV, Plunkett FJ, Salmon M. Differential regulation of CD8+ T cell senescence in mice and men. Mech Ageing Dev 2000;121:69-76.
43. Cossarizza A, Ortolani C, Paganelli R, Barbieri D, Monti D, Sansoni P, Fagiolo U, Castellani G, Bersani F, Londei M, Franceschi C. CD45 isoforms expression on CD4+ and CD8+ T cells throughout life, from newborns to centenarians: implications for T cell memory. Mech Ageing Develop 1996;86:173-95.
44. Rufer N, Brummendorf TH, Kolvraa S, Bischoff C, Christensen K, Wadsworth L, Schulzer M, Lansdorp PM. Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood. J Exp Med 1999;190:157-67.
45. Jenkins MK, Taylor PS, Norton SD, Urdahl KB. CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J Immunol 1991;147:2461-6.
46. Van Lier RAW, Brouwer M, De Jong R, Groot M, De Groot E, Aarden LA, Knapp W (editors). Functional properties of the human T-cell differentiation antigen CD28. Leukocyte typing, vol. IV. Oxford: Oxford University Press; 1989.
47. Azuma M, Phillips JH, Lanier LL. CD28-T lymphocytes. Antigenic and functional properties. J Immunol 1993;4:1147-59.
48. Sepulveda H, Cerwenka A, Morgan T, Dutton RW. CD28 IL-2-independent costimulatory pathways for CD8 T lymphocyte activation. J Immunol 1999;163:1133-42.
49. Effros RB. Replicative senescence of CD8T cells: effect on human ageing. Exp Gerontol 2004;39:517-24.
50. Effros RB. Replicative senescence in the immune system: impact of Hayflick Limit on T cell function in the elderly. Am J Hum Gen 1998;62:1003-7.
51. Campisi J. From cells to organisms: can we learn about ageing from cells in culture? Exp Gerontol 2001;36:607-18.
52. Looney RJ, Falsey A, Campbell D, Torres A, Kolassa J, Brower C, McCann R, Menegus M, McCormick K, Frampton M, Hall W, Abraham GN. Role of cytomegalovirus in the T cell changes seen in elderly individuals. Clin Immunol 1999;90:213-9.
53. Kuijpers TW, Vossen MT, Gent MR, Davin JC, Roos MT, Wertheim-van Dillen PM, Weel JF, Baars PA, Van Lier RA. Frequencies of circulating cytolytic, CD45RA+CD27"CD8+ T lymphocytes depend on infection with CMV. J Immunol 2003;170:4342-8.
54. Khan N, Shariff N, Cobbold M, Bruton R, Ainsworth JA, Sinclair AJ, Nayak L, Moss PA. Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J Immunol 2002;169:1984-92.
55. Ouyang Q, Wagner WM, Wikby A, Remarque E, Pawelec G. Compromised Interferon gamma production in the elderly to both acute and latent viral antigen stimulation: contribution to the immune risk phenotype? Eur Cytokine Netw 2002;13:392-4.
56. Franceschi C, Valensin S, Fagnoni F, Barbi C, Bonafe M. Biomarkers of immunosenescence within an evolutionary perspective: the challenge of heterogeneity and the role of antigenic load. Exp Gerontol 1999;34:911-21
57. Baarle Van D, Tsegaye A, Miedema F, Akbar A. Significance for virus-specific memory T cells responses: rapid ageing during chronic stimulation of he immune system. Immunol Let 2005;97:19-29.
58. Franceschi C, Monti D, Sansoni P, Cossarizza A. The immunology of exceptional individuals: the lesson of centenarians. Immunol Today 1995;16:12-6.
59. Labrie JE, Sah AP, Allman DM, Cancro MP, Gerstein RM. Bone marrow microenvironmental changes underline reduced RAG-mediated recombination and B cell generation in aged mice. J Exp Med 2004;200:411-23.
60. Li F, Jin F, Freitas A, Szabo PI, Weksler ME. Impaired regeneration of the peripheral B cell repertoire from bone marrow following lymphopenia. Eur. J Immunol 2001;31:500-5.
61. Stephan RP, Reilly CR, Witte PL. Impaired ability of bone marrow stromal cell to support B-Lymphoiesis with age. Blood 1998;91:75-88.
62. Chung JB, Silverman M, Monroe JG. Transitional B cells: step by step towards immune competence. Trends Immunol 2003;24:342-8.
63. Kline GH, Hayden TA, Klinman NR. B cell maintenance in aged mice reflects both increased B cell longevity and decreased B cell generation. J Immunol 1999;162:3342-9.
64. Johnson KM, Owen K, Witte PL. Aging and developmental transcisions in the B cell lineage. Int Immunol 2002;14:1313-23.
65. Johnson SA, Rozzo SJ, Cambier JC. Aging-dependent exclusion of antigen-inexperienced cells from the peripheral B cell repertoire. J Immunol 2002;168:5014-23.
66. Weksler ME, Szabo P. The effect of age on the B cell repertoire. J Clin Immunol 2000;20:240-9.
67. Fisman DN, Agrawal D, Leder K: The effect of age on immunologic response to recombinant hepatitis B vaccine: A meta-analysis. Clin Infect Dis 2002;35:1368-75.
68. Zheng B, Han S, Takahashi Y, Kelsoe G. Immunosenescence and germinal center reaction. Immnol Rev 1997;160:63-77.
69. Makinodan T, Kay MM. Age influence on the immune system. Adv Immunol 1980;29:287-330.
70. Goidl EA, Innes JB, Weksler ME. Imunological studies of aging. II. Loss of IgG and high avidity plaque-forming cell and increased suppressor cell activity in aging mice. J Exp Med 1976;144:1037-48.
71. Zharhary D, Segev Y, Gershon H. The affinity and spectrum of cross reactivity of antibody production in senescent mice: The IgM response. Mech. Ageing Dev 1977;6:385-92.
72. Nicoletti C, Yang X, Cerny J. Repertoire diversity of antibody response to bacterial antigen in aged mice: III Phosphorylcholina antibody from young and aged mice differ in structure and protective activity against infection with Streptococcus pneumoniae. J Immunol 1993;150:543-9.
73. Riley SC, et al. Altered VH gene segment utilization in the response to phosphorylcholine by aged mice. J Immunol 1989;143:3798-805.
74. Nicoletti C, Cerny J. The repertoire diversity and magnitude of antibody responses to bacterial antigens in aged mice: I Aged associated changes in antibody responses differ according to the mouse strain. Cell Immunol 1991;33:72-83.
75. Whisler RL, Grants IS. Aged-Related Alterations in the activation and expression of phosphotyrosine kinases and protein kinase C (PKC) among human B cells. Mech Ageing Dev 1993;71:31-46.
76. Eaton SM, Burns EM, Kusser K, Randall TD, Haynes L. Age-related defects in CD4 T cell cognate helper function lead to reductions in humoral responses. J Exp Med 2004;200(12):1613-22.
77. Ershler WB, Moore AL, Socinski MA. Influenza and aging: age-related changes and the effects of thymosin on the antibody response to influenza vaccine. J Clin Immunol 1984;4:445.
78. Ershler WB, Moore AL, Socinski MA. Influenza and aging: age-related changes and the effects of thymosin on the antibody response to influenza vaccine. J Clin Immunol 1984;4:445.
79. McLachlan JA, Serkin CD, Morrey KM, Bakouche O. Antitumoral properties of aged human monocytes. J Immunol 1995;154:832.
80. Lloberas J, Celada A. Effect of aging on macrophage function. Exp Gerontol 2003;37(12):1325-31.
81. Renshaw M, Rockwell J, Engleman C, Gewirtz A, Katz J, Sambhara S. Cutting edge: impaired Toll-like receptor expression and function in aging. J Immunol 2002;169(9):4697-701.
82. Provinciali M, Smorlesi A. Immunoprevention and immunotherapy of cancer in ageing. Can Immunol Immunother 2005;54:93-106.
83. Rink I, Cakman I, Kirehner H. Altered cytokine production in the elderly. Mech Ageing Dev 1998;102:109.
84. Steger MM, Maczek C, Grubeck-Loebenstein B. Morphologically and functionally intact dendritic cells can be derived from the peripheral blood of aged individuals. Clin Exp Immunol 1996;105:544.
85. Uyemura K, Castle S, Makinodan T. The frail elderly: role of dendritic cells in the susceptibility of infection. Mech Ageing Dev 2002;123(8):955-62.
86. Sprecher, et al. Effect of aging on epidermal dendritic cell populations in C57BL/6J mice. J Invest Dermatol 1990;94(2):247-53.
87. Solana R, Mariani E. NK and NK/T cells in human senescence. Vaccine 2000;18(16):1613-20.
88. Ginaldi M, De Martinis M, D'Ostilio A, Marini L, Loreto MF, Quaglino D. The immune system in the elderly: III. Innate Immunity. Imunol Res 1999;20:117-26.
89. Wikby, A, et al. Age-related changes in immune parameters in a very old population of Swedish people: a longitudinal study. Exp Gerontol 1994;29:531-41.
90. th session of British Society for Immunology annual Congress, Harrogate, December 2004. Immunity & Ageing 2005;2:5.
91. Ferguson FG, et al. Immune parameters in a longitudinal study of a very old population of Swedish people: a comparison between survivors and nonsurvivors. J. Gerontol. A Biol Sci Med Sci 1995;50:378-82.
92. Pawelec G, et al. The SENIEUR protocol after 16 years. Mech Ageing Dev 2001;122:132-4.
93. Olsson J, et al. Age-related change in peripheral blood T-lymphocyte subpopulations and cytomegalovirus infection in the very old: the Swedish longitudinal OCTO immune study. Mech Ageing Dev 2000;121:187-201.
94. Pawelec G, Akbar A, Caruso C, Efrros R, Grubeck-Loebenstein, Wikby A. Is immnosenescence infectious? Trends Immunol 2004;25(8):406-10.
95. Pawelec G, Ouyang Q, Wagner W, Biol D, Wikby A. Pathways to a robust immune response in the elderly. Immunol. Allergy Clin North Am 2003;23:1-13.
96. Ouyang, Q, et al. Age-associated accumulation of CMV-specific CD8+ Tcells expressing the inhibitory killer cell lectin-like receptor G1 (KLRG1). Exp Gerontol 2003;38:911-20.
97. Nilsson BO, et al. Morbidity does not influence the T cell immune risk phenotype in the elderly: findings in the Swedish NONA immune study using sample selection protocols. Mech Ageing Dev 2003;124:469-76.
98. Pawelec G, Ouyang Q, Colona-Romano G, Candore G, Lio D, Caruso C. Is human immunoenescence clinically relevant? Looking for immunological risk phenotype. Trends immunol 2002;23:330-2.
99. Pawelec G. Immunosenescence and human longevity. Biogerontology 2003;4:167-70.
100. Cui Z, Willigham MC. The effect of aging on cellular immunity against cancer in SR/CR mice. Cancer Immunol Immunother 2004;53:473-8.
101. Erlich P. Ueber den jetzigen stand der Karzinomfors-chung. Ned Tijdschr Geneeskd 1909;5:273.
102. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991.
103. Dunn GP, Old LJ, Schreiber RD. The Immunobiology of Cancer Immunosurveillance and Immunoediting. Immunity 2004;21:137-48.
104. Street SE, Cretney E, Smyth MJ. Perforin and inter-van feron gamma activities independently control tumor initiation, growth, and metastasis. Blood 2001;97:192-7.
105. Street SE, Trapani JA, MacGregor D, Smyth MJ. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med 2002;196:129-34.
106. Smyth MJ, Crowe, NY, Godfrey DI. NK cells and NKT cells collaborate in host protection from methylcholanthrene induced fibrosarcoma. Int Immunol 2001;13:459-63.
107. Dunn GP, Old LJ, Schreiber RD. The Three Es of Cancer Immunoediting. Annu Rev Immunol 2004;22:329-60.
108. Walker PR, Saas P, Dietrich PY. Role of Fas Ligand(CD95L) in immune escape: the tumor cell strikes back. J Immunol 1997;158:4521.
109. Zhou D, Chrest FJ, Adler W, Munster A, Winchurch RA. Increased production of TGF-beta and IL-6 by aged spleen cells. Immunol Lett 1993;36:7.
110. Cavallo F, Signorelli P, Giovarelli M, et al. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J. Natl Cancer Inst 1997;89(14):1049-58.
111. Colombo MP, Forni G. Cytokine gene transfer in tumor inhibition and tumor therapy: Where are we now? Immunol Today 1994;15(2):48-51.
112. Goronzy JJ, Weyand CM. T cells senescence and contraction of T cell repertoire diversity-catalysts of autoimmunity and chronic inflammation. Arthritis Res Ther 2003;5:225-34.
113. Weyand CM, Fulbright JW, Goronzy JJ. Immunosenescence, autoimmunity and rheumatoid arthritis. Exp Gerontol 2003;38(8):833-41.
114. Pawelec G, Solana R. Immunosenescence. Trend Immunol 1997;11:514.
115. Pawelec G, Hirokawa K, Fulop T. Altered T cells signalling in ageing. Mech Ageing Dev 2001;122:1613.
116. Kapasi ZF, Murali-Krishna K, Mc Rae ML, Ahmed R. Defective generation but normal maintenance of memory T cells in old mice. Eur J Immunol 2002;32:1567.
117. Donnini A, Argentati K, Mancini R, Smorlesi A, Bartozzi B, Bernardini G, Provinciali M. Phenotype antigen-presenting capacity and migration of antigen-presenting cells in young and old age. Exp Gerontol 2002;37:1097.
118. Pawelec G, Solana R, Remarque ED, Mariani E. Impact of aging on innate immunity. J Leukoc Biol 1998;64:703.
119. Provinciali M, Di Stefano G, Colombo M, Della Croce F, Gandolfi MC, Daghetta L, Anichini M, Della Bitta R, Fabris N. Adjuvant effect of low-dose interleukin-2 on antibody response to influenza virus vaccination in healthy elderly subjects. Mech Ageing Dev 1994;77:75.
120. Provinciali M, Montenovo A, Di Stefano G, Colombo M, Daghetta L, Cairati M, Veroni C, Cassini R, Della Torre F, Fabris N. Effect of zinc or zinc plus arginine supplementation on antibody titer and Lymphocyte subsets after influenza virus vaccination in elderly subjects. Age Ageing 1998;27:715.
121. Jackson LA, Neuzil KM, Yu O, Benson P, Barlow WE, Adams AL, Hanson CA, Mahoney LD, Shay DK, Thompson WW. Effectiveness of pneumococal polysaccharide vaccine in older adults. N Engl J Med 2003;348:1747.
122. Steger MM, Maczek C, Berger P, Grubeck-Lobenstein B. Vaccination against tetanus in the elderly: do recommended vaccination strategies give sufficient protection? Lancet 1996;348:762.
123. Wolters B, Junge U, Dziuba S, Roggendorf M. Immunogenicity of combined hepatitis a and B vaccine in elderly persons. Vaccine 2003;21:3623.
124. Lage A, Pérez R, Fernández LE. Therapeutic cancervaccines: At midway between Immunology and Pharmacology. Curr Cancer Drug Targets 2005;5:611-27.
125. Provinciali M, Argentati K, Tibaldi A. Efficacy of cancer gene therapy in ageing: adenoarcinoma cells engineered to release I-2 are rejected but do not induce tumor specific immune memory in old mice. Gene Ther 2000;7:624-32.
126. Provinciali M, Smorlesi A, Donnini A, Bartozzi B, Amici A. Low of DNA vaccination against HER-2/neu in ageing. Vaccine 2003;21:843-8.
127. Rosemberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettighausen JE, Matori YL, Skibberg JM, Shiloni E, Vetto JV, Seipp CA, Simpson C, Reichert CM. Obsarvationson the systemic administration of autologus lymphokine-activated killr cells and recombinant IL-2, to patients with metastatic cancer. N Engl J Med 1985;313:1485.
128. Rosemberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan WM, Seipp CA, White DE, Steinberg SM. Prospective randomized trial of high dose interleukin-2 alone or in conjunction with lymphokine activated killer cell for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993;85:622.
129. Finn OJ. Cancer vaccines: between the idea and the reality. Nat Immunol 2003;3:60.
130. Ko BK, Murray JL, Disis ML, Efferson CL, Kuerer HM, Peoples GE, Ioannides CG. Clinical studies of vaccine targeting breast cancer. Clin Cancer Res 2003;9:3222.
131. Lollini P-L, Forni G. Cancer immunoprevention: tracking down persistent tumor antigens. Trends Immunol 2003;24:62.